JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients

  • 0Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Plos One +

|

September 6, 2024

|

September 6, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Prostate cancer patients with lung metastases had better survival. Liver metastases indicated worse outcomes, especially with multiple sites or bone involvement. Asian patients generally had improved survival.

Area Of Science

  • Oncology
  • Medical Statistics

Background

  • Visceral metastasis is a key predictor of poor outcomes in prostate cancer.
  • The prognostic impact of specific visceral metastatic sites is not well understood.

Purpose Of The Study

  • To investigate the effect of different visceral metastatic sites on survival in prostate cancer patients.

Main Methods

  • Utilized the TriNetX database to identify metastatic prostate cancer patients (2010-2023).
  • Categorized patients into cohorts based on metastatic sites: lung, brain, liver, and bone.
  • Conducted survival analysis using Kaplan-Meier and Cox regression models.

Main Results

  • Analyzed 59,875 patients; bone (65.2%), lung (12.5%), brain (8.7%), and liver (12.5%) metastases were observed.
  • Median overall survival: bone (44.4 months), lung (31.9 months), liver (10 months), brain (9.6 months).
  • Lung metastases showed better survival than liver and brain. Liver metastases correlated with worse outcomes in multi-site or bone-metastatic disease. Asian patients had better survival.

Conclusions

  • Lung metastases associated with better survival in single-site visceral metastasis.
  • Liver metastases linked to worse outcomes in multi-site visceral or bone-metastatic prostate cancer.
  • Asian patients demonstrated improved survival compared to Caucasian and African American patients.